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Endoglin (ENG) is a transmembrane glycoprotein expressed on endothelial cells that
functions as a co-receptor for several ligands of the transforming growth factor beta
(TGF-β) family. ENG is also a recognized marker of angiogenesis and mutations in the
endoglin gene are responsible for Hereditary Hemorrhagic Telangiectasia (HHT) type 1, a
vascular disease characterized by defective angiogenesis, arteriovenous malformations,
telangiectasia, and epistaxis. In addition to its involvement in the TGF-β family signaling
pathways, several lines of evidence suggest that the extracellular domain of ENG has
a role in integrin-mediated cell adhesion via its RGD motif. Indeed, we have described
a role for endothelial ENG in leukocyte trafficking and extravasation via its binding to
leukocyte integrins. We have also found that ENG is involved in vasculogenic properties of
endothelial progenitor cells known as endothelial colony forming cells (ECFCs). Moreover,
the binding of endothelial ENG to platelet integrins regulate the resistance to shear during
platelet-endothelium interactions under inflammatory conditions. Because of the need for
more effective treatments in HHT and the involvement of ENG in angiogenesis, current
studies are aimed at identifying novel biological functions of ENG which could serve as
a therapeutic target. This review focuses on the interaction between ENG and integrins
with the aim to better understand the role of this protein in blood vessel formation driven
by progenitor and mature endothelial cells.
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ENDOGLIN STRUCTURE AND FUNCTION
Endoglin (ENG; also known as CD105) is a type I transmembrane glycoprotein predominantly
expressed in endothelial cells (ECs) (1, 2) and endothelial colony-forming cells (ECFCs)
(3). It is known as an essential co-receptor for the transforming growth factor β (TGF-
β) family, playing an important role in angiogenesis. At the cell surface, ENG associates
with TGF-β type I receptors, including the ECs-specific ALK1 (activin receptor-like kinase
1) and the ubiquitous ALK5, as well as to a TGF-β type II receptor. In this receptor
complex, ENG and ALK1 are able to bind to bone morphogenetic protein 9 (BMP9;
also known as growth differentiation factor 2 [GDF2]), a member of the TGF-β family,
with much higher affinity than to TGF-β1 and mediate its proliferation signal (4–7).
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Upon ligand binding, the TGF-β signaling receptor complex
phosphorylates members of the Smad family of transcription
factors which, in turn, undergo nuclear translocation to regulate
gene expression (Figure 1A).
In addition to the membrane bound form of endoglin,
a circulating form of the ENG ectodomain, was found to
be released upon a C-terminal cleavage of ENG by matrix
metalloproteinase 14 (MMP-14) (8, 9). Increased levels of
circulating endoglin have been detected at early stages of
preeclampsia (5, 10) in hypertensive or diabetic patients (11)
and in certain cancer patients (12), suggesting its role as
a predictive biomarker in these pathologies. Interestingly,
a detailed characterization of plasma from women with
preeclampsia has revealed that circulating endoglin can be
complexed within exosomes, rather than as individual soluble
endoglin (13).
A pioneer article on human ENG described that this
glycoprotein is present on ECs as a dimer (two subunits
of ∼90-kDa), each displaying the tripeptide arginine-glycine-
aspartic acid (RGD) in the extracellular region of the protein
(1). The RGD motif and homologous sequences in mouse
and pig are recognition motifs for cell surface integrins
present in extracellular matrix proteins such as fibronectin,
tenascin, thrombospondin, vitronectin, von Willebrand factor
as well as fibrinogen and prothrombin (14–16). Integrin-
mediated adhesion is involved in hemostasis, thrombosis, and
inflammation, processes in which the endothelium plays a
critical role. Therefore, the presence of the RGD motif within
a hydrophilic environment (1) and its accessibility in the 3D
structure of ENG (7), clearly suggest the involvement of ENG
in integrin binding, as postulated in early studies (17, 18). In
fact, endothelial endoglin binds to leukocyte integrins, allowing
leukocyte extravasation (19) suggesting a possible novel function
for ENG independent of TGF-β signaling (Figures 1B,C). Several
lines of evidence support the role of ENG in leukocyte trafficking:
(i) ENG expression is markedly up regulated in endothelial cells
of inflamed tissues with an associated inflammatory cell infiltrate
(19); (ii) ENG is up-regulated in the post-ischemic kidney and
ENG-haploinsufficient mice are protected from renal ischemia-
reperfusion injury, due to a reduction of cellular inflammatory
responses (20); (iii) Arterial, venous, and capillary endothelia in
lymphoid organs are highly reactive with anti-ENG antibodies
and a marked staining pattern is observed in high endothelial
venules (21); and (iv) Although ENG is present throughout
the vascular endothelium, its expression, as compared to veins
or arteries, is stronger in capillaries, where most leukocyte
infiltration to organs occurs.
In addition to leukocytes, other cell types present in the
circulatory system have also revealed an integrin-mediated
adhesion activity toward endothelial endoglin (22–24)
(Figures 1D,E). Thus, endoglin plays a role in integrin-mediated
adhesion of vascular mural cells to endothelium (23). Also, a
new role for endoglin in αIIbβ3 integrin-mediated adhesion of
platelets to the endothelium, conferring resistance of adherent
platelets to detachment has been described (24) (Figure 1E).
VASCULAR PATHOPHYSIOLOGY OF
ENDOGLIN IN HEREDITARY HEMORRAGIC
TELANGECTASIA (HHT)
Hereditary Hemorrhagic Telangiectasia (HHT) is an
autosomal dominant disease with a prevalence of one case
per 5,000–8,000 individuals (25, 26). HHT patients develop
muco-cutaneous lesions known as telangiectasia in the nose,
mouth, and gastrointestinal tract, as well as larger AVMs
in major organs such as the lung, liver, and brain (25). The
telangiectasia are comprised of fragile vessels that are susceptible
to rupture and hemorrhage, which means that HHT patients can
suffer recurrent anemia following frequent and severe bleeding
episodes. Mutations in the endoglin gene (ENG) are responsible
for HHT type 1 (HHT1) (27), while mutations in activing
receptor-like kinase (ACVRL1 alias ALK1) are responsible for
HHT2 (2, 27). Taken together, HHT1 and HHT2 account for
more than 80% of all HHT cases, whereas a small number of
patients show mutations in SMAD4 (MADH4) or in BMP9
gene (GDF2), which are responsible for less common HHT
variants such as a combined syndrome with juvenile polyposis
(JP-HHT) and HHT5, respectively (28, 29). Remarkably, all
of these genes code for proteins involved in the TGF-β family
signaling pathways (30). Nowadays, the most widely accepted
hypotheses for AVMs formation in HHT1 and HHT2 involves
a “first hit” (gene haploinsufficiency) based on the loss of
one functional allele Eng+/− (HHT1) or ALK1+/− (HHT2),
which causes a 50% reduction in protein expression, followed
by a “second hit” based on an angiogenic trigger such as
inflammation, hypoxia or vascular injury (31). Together, these
events may induce a deficient endothelial function of ENG
that could result in HHT vascular lesions. The relevant role
of endoglin in the pathophysiology of the vascular system
is illustrated by the phenotype of different HHT1 animal
models (32). While endoglin heterozygous mice are viable
and reproduce the vascular phenotype of HHT patients, total
loss of ENG expression leads in mice to cardiovascular defects
and embryonic death by mid-gestation (33–35). A conditional
knock out mouse model for HHT1 has revealed that the
arteriovenous malformations (AVMs), induced upon ENG
loss, appear to be the result of delayed vascular remodeling
and inappropriate ECs proliferation responses (36). In ENG
null mice, vasculogenesis does not seem affected, suggesting
that ENG is not required for initial differentiation of ECs or
formation of a primitive vascular plexus. The yolk sac of Eng−/−
embryos has enlarged fragile vessels, while the embryo proper
shows cardiac cushion defects and delayed maturation of major
vessels (34). The reason why the total loss of ENG expression
leads to cardiovascular defects and embryonic death is not
completely understood. Some authors have postulated that
the primary defect is in the heart (37), while others suggest
that the loss of smooth muscle cells (SMCs) coverage of the
endothelium could play a decisive role in the lethality of Eng−/−
animals (34).
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FIGURE 1 | Hypothetical model of Endoglin and its role as TGF-β co-receptor and adhesion molecule in different physiological contexts. (A) Canonical pathway that
implicates Eng as a co-receptor of TGF-β in ECs. Bone morphogenetic protein 9 (BMP9), and other members of the TGF-β family, bind to an EC receptor complex
composed by the type I (R-I) receptor named ALK1 and the type II (R-II) receptor, both exhibiting serine/threonine kinase activity, as well as the auxiliary receptor
endoglin. Upon ligand binding, the R-II transphosphorylates ALK1, which subsequently propagates the signal by phosphorylating the receptor-regulated Smad
(R-Smad) family of proteins Smad1/5/8. Phosphorylated R-Smads form heteromeric complexes with Smad4, translocating into the nucleus to regulate the
transcriptional activity of different target genes. BMP9, Endoglin, ALK1 and Smad4 proteins are encoded by GDF2, ENG, ACVRL1 and MADH4 genes, whose
pathogenic mutations give rise to HHT5, HHT1, HHT2, and JPHT, respectively (30). (B) Endothelial endoglin as an adhesion molecule involving its RGD sequence
when binding to cell surface integrins from leukocytes, VMCs or platelets. (C) Leukocyte transmigration through the vessel endothelium. Under inflammatory
conditions, different soluble factors are released leading to leukocyte adhesion and transmigration through ECs. This process is mediated, at least, by the interaction
between leukocyte integrin α5β1 and endothelial endoglin involving the specific recognition of the RGD motif in Eng (22). (D) Adhesion between endothelial cells and
vascular mural cells (VMCs). This intercellular association involves, at least, the interaction between integrin α5β1 in VMCs and endothelial endoglin via the specific
recognition of the RGD motif in Eng (23). (E) Platelet-dependent hemostasis. Endothelial endoglin via its RGD binds to platelet integrins αIIbβ3 and α5β1, contributing
to stabilize platelets adhesion to endothelium (24).
ENDOGLIN INTERACTING PARTNERS IN
THE VASCULATURE
Previous studies reported that endothelial ENG is associated with
several proteins critically involved in endothelial cell adhesion,
proliferation, migration, angiogenesis, and vascular permeability,
including integrins (38), zyxin (39), zyxin-related protein 1
(ZRP-1) (40), VEGF receptor type 2 (VEGFR-2) (41), beta-
arrestin 2 (42), and vascular endothelial-cadherin (VE-cadherin)
(43). It has been shown that VE-cadherin interacts with several
components of the TGF-β receptor complex, including ENG,
ALK1, and the TGF-β type II receptor TGFBR2 in adherents
junctions. Of note, ENG, TGFBR2, and ALK1 also interact
with p21-activated kinase (PAK-1), GTP-binding proteins, and
Ras-related C3 botulinum toxin substrate 2 (Rac-2), involved
in endothelial barrier maintenance, cytoskeletal remodeling
and cell migration (44). Using in vitro ECs lines derived
from ENG homozygous null, heterozygous, and control mouse
embryos, Jerkic and Letarte have reported that ENG-deficient
mouse embryonic ECs are hyper-permeable and unresponsive
to stimulation by VEGF and TGF-β1, factors that regulate
vascular permeability (45). Interestingly, VE-cadherin is barely
detected in ENG-deficient ECs, a finding that could explain
the EC junction destabilization and impairment of TGF-
β signaling. Furthermore, permeability alterations in Eng+/−
mice are in line with findings in patients with Hereditary
Hemorrhagic Telangiectasia type 1 (HHT1). Thus, ECs from
HHT1 patients show a disorganized actin cytoskeleton prone to
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cell breaking with changes in shear stress and blood pressure
(46). This reorganization of actin filaments in HHT1 might
lead to vessel hemorrhages and eventual disappearance of the
capillary network, as reported in this disorder. In line with the
pathogenic hypothesis of an endothelial dysfunction in HHT1,
the involvement of ENG in integrin-mediated trans-endothelial
leukocyte trafficking was proposed (31). Accordingly, following
inflammation triggering, the extracellular region of ENG binds to
leukocyte integrin α5β1 and promotes leukocyte transmigration
(31). In contrast, a different experimental approach showed an
increased gut inflammation and myeloid infiltration in colitis
Eng+/− vs. control mice (47). Overall, this novel role of ENGmay
contribute to a better understanding of the inflammation process
and the high incidence of infections in HHT patients (48).
Because pericytes embrace the endothelium to regulate the blood
retinal barrier, the role of endothelial endoglin in this context
has also been analyzed. Thus, vascular permeability studies
carried out in vivo showed that retinas of Eng+/− heterozygous
mice displayed higher retinal permeability than that of Eng+/+
mice, suggesting a destabilization of the endothelial barrier
function due to ENG haploinsufficiency (23). The importance
of the interaction between ECs and vascular mural cells is
also underlined by studies showing that thalidomide stabilizes
the vasculature in a mouse model of HHT1 (49). Indeed,
pericyte recruitment and stabilization appears as a therapeutic
strategy to reduce the severity of epistaxis in HHT (50). Thus,
ENG, directly, or as a component of the TGF-β receptor
complex may regulate ECs integrity, whereas its absence may
result in vascular hyper-permeability, thus contributing to the
fetal lethality associated with the homozygous null genotype
(39, 40).
Although this review focuses on the role of endoglin in
ECs, it is worth mentioning that endoglin is also expressed
at lower levels in other cell types, some of which present
in the vasculature as vascular SMCs, activated monocytes or
mesenchymal cells (18, 51–53). However, a review on the
endoglin role in these cell types deserves an independent
study.
ENDOGLIN AND ENDOTHELIAL
COLONIES FORMING CELLS (ECFCS)
The formation of blood vessels from mesoderm is driven by the
recruitment of undifferentiated cells which can differentiate into
endothelial lineage. In the adult, populations of bone marrow-
derived endothelial progenitor cells (EPCs) are mobilized into
the circulation by stimuli such as estrogen and VEGF (54).
Interestingly, human EPCs could derive from very small
embryonic like stem cells (55) that can also give rise to
hematopoietic cells (56). Two populations of EPCs have
been differentially characterized from circulating endothelial
progenitors: (i) early EPCs that exhibit a hematopoietic profile
with a genomic fingerprint similar to monocytes; and (ii) ECFCs,
also known as blood outgrowth endothelial cells (BOECs), which
are considered late EPCs with an endothelial-like genomic profile
(57). ECFCs display an intrinsic tube forming capacity in vitro
and in vivo and they are involved in blood vessel formation and
vascular repair (58, 59). For example, upon vascular injury, tissue
perfusion of blood flow involves not only angiogenic sprouting
of ECs from nearby intact vessels, but also the recruitment
circulating ECFCs allowing the formation of new blood vessels
(60). Acting at the interface between blood and tissues, ECFCs
have a remarkable ability for migration and proliferation,
being key cells in angiogenesis and vascular remodeling. It
is therefore not surprising that perturbations in these critical
ECFCs functions contribute to several vascular pathologies.
Accordingly, ECFCs have opened a new area for treatment
of cardiovascular diseases using cell therapy, advancing in the
knowledge of vessel reconstruction ability in postnatal life. In
this line, much effort has been recently devoted to identify
novel molecular targets within ECFCs able to enhance their
angiogenic potential. ECFCs are positive for endoglin (CD105),
VE-cadherin (CD144), CD31, VEGFR2 (KDR), EGFL7, and
CD146, and negative for CD45 and CD14 (58, 59). Among these,
ENG is emerging as an interesting therapeutic target based on its
involvement in angiogenesis and vascular remodeling (46, 61).
Many strategies of therapeutic revascularization, based on
the administration of growth factors or stem/progenitor cells
from diverse sources including EPCs, have been proposed
and are currently being tested in patients with peripheral
arterial disease or cardiac diseases (62). Some pretreatment of
ECFCs with erythropoietin (63), fucoidan (64), soluble CD146
(65), tumor necrosis factor-α (TNF-α) (66), or platelet lysates
(67, 68) have also been proposed to improve the therapeutic
efficacy of in vivo administered ECFCs. Interestingly, integrins
represent a major molecular determinant of EPCs function. More
specifically, integrin α4β1 is a key regulator of EPCs retention
and/or mobilization from the bone marrow, while integrins
α5β1, α6β1, αvβ3, and αvβ5 are involved in EPCs homing,
invasion, differentiation and paracrine factor production (69).
The involvement of ECFCs in angiogenesis has been shown to
be essential for ischemic disease recovery (70, 71). Furthermore,
the differentiation of mesenchymal stem cells (MSCs) into mural
cells appears to be stimulated by their co-culture with ECFCs,
whereas overexpression of the Notch ligand Jagged1 in ECs
further enhanced the differentiation of MSC into pericytes
(72). This cooperation prompted some authors to postulate
an improvement of ECFCs efficiency by co-injecting ECFCs
and SMC progenitors (73). Therefore, a combined treatment of
ECFCs with mesenchymal stem/progenitor cells (MSCs/MPCs)
appears to operate synergistically, enhancing neovascularization
compared to either individual cell population (74, 75). Recently,
we proposed a role for ENG in the ECFCs-MSCs interplay
involved in the revascularization process (61). Indeed, ENG
silencing in ECFCs markedly inhibited ECFCs adhesion to MSCs
in vitro, without affecting MSCs differentiation into perivascular
cells or other mesenchymal lineages. Mesenchymal stem cells
(MSCs) increase muscle recovery of ECFC in HLI model and
we found that ENG-silenced ECFCs co-injected with MSCs in
mice abolish beneficial effects ofMSCs leading to decreased vessel
density and foot perfusion upon ischemia. Our results suggest
ENG involvement in the crosstalk between ECFCs and MSCs,
leading to vessel formation and stabilization (51) (Figures 2A,B).
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FIGURE 2 | Endoglin in ECFCs. (A) Role of endoglin matrigel vascularization in vivo. Matrigel plugs were mixed with either ECFCs treated with control siRNA plus
mesenchymal stem cells (MSCs) (left) or with ECFCs treated with endoglin specific siRNA plus MSCs (right). The Matrigel mixture was injected into nude mice and the
number of vessels was analyzed after 1 week. Control plugs display a marked vascularization with functional vessels (presence of erythrocytes). Plugs with
endoglin-silenced ECFCs display less vascularization than controls, suggesting an important role for this protein in cell adhesion (23). (B) MSCs combined with
ECFCs, accelerate muscle recovery in a mouse model of hind limb ischemia, through an endoglin-dependent mechanism. After femoral ligature and retro-orbital
injection of ECFC+MSC Doppler analysis shows a revascularization induced by co-injection of ECFCs plus MSCs (left). This synergistic effect is abolished when
endoglin is previously silenced in ECFCs (right) (61). (C) Mechanisms involved in the synergy between ECFCs and MSCs. (i) Mutual paracrine effect between ECFCs
and MSCs involving growth factors like VEGF and PDGFBB (76, 77). (ii) ECFCs-induced differentiation of MSCs into perivascular cells via Notch-Jagged1 (72) (iii)
Adhesion between ECFCs and MSCs involving endoglin (61).
As postulated in Figure 2C, three steps may be involved
during the formation of stable vessels by ECFC and MSC
and/or perivascular cells: (i) Mutual paracrine effects by VEGF
and/or PDGF-BB (76, 77). (ii) ECFCs-driven perivascular
maturation of MSC and/or SMC progenitors via the notch-
dependent pathway; and (iii) Adhesion between ECFCs
and perivascular cells in an ENG-dependent manner.
The relevance of endothelial ENG adhesive properties in
mature vessel formation in mice (61) is in agreement with
a previous report on the active role of human ENG in the
adhesion between mature ECs and vascular mural cells
(23).
Relevance of ENG in ECFC has been demonstrated also
in ECFCs isolated directly from HHT1 patients. Indeed, these
ECFCs have disorganized and depolymerized actin fibers and
impaired tube formation, as compared to healthy ECFCs (46).
The molecular basis for the abnormal behavior of HHT1 ECFCs
appears to be mediated, at least in part, by the regulatory
role of endoglin and we can speculate via its interaction
with zyxin family members involved in the actin cytoskeletal
organization as it was proposed for endothelial cells (39, 40).
Thus, the ENG cytoplasmic domain binds to zyxin and ZRP1,
which concentrate at focal adhesions within actin polymerization
points. Consequently, the decrease of ENG levels in HHT1
ECFCs could be related to the cytoskeleton alteration.
CONCLUSION
Blood vessel formation and remodeling are essential processes
in the maintenance of tissue homeostasis and function,
and therefore, their alteration causes a variety of pathologic
conditions. ENG involvement in the function of mature and
progenitor endothelial cells is a hot topic not completely
understood and developed yet. Recent findings underline
the importance of ENG not only as a co-receptor for several
ligands of the TGF-β family, but also as a molecule involved
in cell adhesion, which can regulate ECFCs behavior in
the context of angiogenic processes. It is recognized that
in mature ECs, ENG plays a key role in angiogenesis and
blood vessel homeostasis, becoming a potential therapeutic
target for pro- and anti-angiogenic approaches in the
treatment of diseases such as HHT, cancer, preeclampsia,
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diabetes complications or post-ischemic disease. While ENG
expression is relatively low in quiescent ECs, it is upregulated
in the active endothelium involved in angiogenesis and
vessel remodeling and permeability. In these processes,
endothelial ENG regulates ECs proliferation, migration, and
actin cytoskeletal organization, leukocyte extravasation, and
interaction with mural cells. In addition, a role for ENG in
platelet-endothelium interaction, including the resistance of
adherent platelets to shear under inflammatory conditions,
was also recently proposed, opening new perspectives on ENG
functions.
This review highlights the emerging roles of endothelial
ENG as a cell adhesion molecule in mature and progenitor
endothelial cells interacting with vascular mural cells, leukocytes,
and platelets, independently or in parallel to its TGF-β co-
receptor role.
While evidence-based therapeutics are coming into play in
the traditionally empirical base for endoglin related protein
derivatives, future studies of ENG in endothelial progenitor cells
may pave the way for a better understanding of its function in the
vascular system and for the development and understanding of
the use of these immature cells as a cell therapy product.
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